These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26475253)

  • 21. Effect of PBPK model structure on interpretation of in vivo human aqueous dermal exposure trials.
    Norman AM; Kissel JC; Shirai JH; Smith JA; Stumbaugh KL; Bunge AL
    Toxicol Sci; 2008 Jul; 104(1):210-7. PubMed ID: 18381354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier.
    Gratieri T; Kalia YN
    Adv Drug Deliv Rev; 2013 Feb; 65(2):315-29. PubMed ID: 22626977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of drug permeation through human skin.
    Chandrasekaran SK; Bayne W; Shaw JE
    J Pharm Sci; 1978 Oct; 67(10):1370-4. PubMed ID: 702282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measurement of bioavailability: measuring absorption through skin in vivo in rats and humans.
    Bounds SV; Hawkins DR
    Curr Protoc Toxicol; 2001 May; Chapter 5():Unit5.2. PubMed ID: 20949435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis, interpretation, and extrapolation of dermal permeation data using diffusion-based mathematical models.
    Krüse J; Golden D; Wilkinson S; Williams F; Kezic S; Corish J
    J Pharm Sci; 2007 Mar; 96(3):682-703. PubMed ID: 17080423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Skin permeation: the years of enlightenment.
    Hadgraft J; Lane ME
    Int J Pharm; 2005 Nov; 305(1-2):2-12. PubMed ID: 16246513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysing the skin barrier from down under.
    Grice J; Benson HA
    Skin Pharmacol Physiol; 2013; 26(4-6):254-62. PubMed ID: 23921112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the effect of experimental variables on the in vitro permeation of six model compounds across porcine skin.
    Karadzovska D; Brooks JD; Riviere JE
    Int J Pharm; 2013 Feb; 443(1-2):58-67. PubMed ID: 23313919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The margin of internal exposure (MOIE) concept for dermal risk assessment based on oral toxicity data - A case study with caffeine.
    Bessems JGM; Paini A; Gajewska M; Worth A
    Toxicology; 2017 Dec; 392():119-129. PubMed ID: 28288858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomes and skin: from drug delivery to model membranes.
    El Maghraby GM; Barry BW; Williams AC
    Eur J Pharm Sci; 2008 Aug; 34(4-5):203-22. PubMed ID: 18572392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroquinone PBPK model refinement and application to dermal exposure.
    Poet TS; Carlton BD; Deyo JA; Hinderliter PM
    Food Chem Toxicol; 2010 Nov; 48(11):3085-92. PubMed ID: 20692312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting vehicle effects on the dermal absorption of halogenated methanes using physiologically based modeling.
    Jepson GW; McDougal JN
    Toxicol Sci; 1999 Apr; 48(2):180-8. PubMed ID: 10353309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a human physiologically based pharmacokinetic (PBPK) model for dermal permeability for lindane.
    Sawyer ME; Evans MV; Wilson CA; Beesley LJ; Leon LS; Eklund CR; Croom EL; Pegram RA
    Toxicol Lett; 2016 Mar; 245():106-9. PubMed ID: 26794662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in predicting skin permeability of hydrophilic solutes.
    Chen L; Han L; Lian G
    Adv Drug Deliv Rev; 2013 Feb; 65(2):295-305. PubMed ID: 22580335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonlinear pharmacokinetics relative to toxicity and use of toxicological data.
    Ramsey JC
    Drug Metab Rev; 1982; 13(5):779-97. PubMed ID: 6754308
    [No Abstract]   [Full Text] [Related]  

  • 38. A physiologically based pharmacokinetic model of organophosphate dermal absorption.
    van der Merwe D; Brooks JD; Gehring R; Baynes RE; Monteiro-Riviere NA; Riviere JE
    Toxicol Sci; 2006 Jan; 89(1):188-204. PubMed ID: 16221965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of physiologically-based toxicokinetic modelling in oral-to-dermal extrapolation of threshold doses of cosmetic ingredients.
    Gajewska M; Worth A; Urani C; Briesen H; Schramm KW
    Toxicol Lett; 2014 Jun; 227(3):189-202. PubMed ID: 24731971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models.
    Godin B; Touitou E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1152-61. PubMed ID: 17889400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.